With diabetes (N = 184) | Without diabetes (N = 1928) | p value | |
---|---|---|---|
Age (years) | < 0.0001 | ||
Mean (SD) | 56.5 (9.4) | 51.0 (12.1) | |
Sex, n (%) | 0.3348 | ||
Female | 146 (79.3) | 1585 (82.2) | |
Male | 38 (20.7) | 343 (17.8) | |
Race, n (%) | 0.0907 | ||
Caucasian/White | 147 (79.9) | 1607 (83.4) | |
Black | 8 (4.3) | 44 (2.3) | |
Asian | 15 (8.2) | 99 (5.1) | |
Other | 14 (7.6) | 178 (9.2) | |
Weight (kg) | < 0.0001 | ||
Mean (SD) | 84.08 (21.59) | 74.04 (18.76) | |
Body mass index (kg/m2) | < 0.0001 | ||
Mean (SD) | 32.18 (7.40) | 28.04 (6.38) | |
Duration of RA since diagnosis (years) | 0.6294 | ||
Mean (SD) | 9.82 (8.81) | 9.51 (8.44) | |
Rheumatoid factor, n (%) | 0.0964 | ||
Positive | 136 (74.3) | 1517 (79.5) | |
Negative | 47 (25.7) | 390 (20.5) | |
Anti CCP antibody, n (%) | 0.0593 | ||
Positive | 143 (77.7) | 1587 (83.2) | |
Negative | 41 (22.3) | 320 (16.8) | |
Tender joint count (0–68) | 0.0017 | ||
Mean (SD) | 30.97 (15.92) | 27.11 (14.11) | |
Swollen joint count (0–66) | 0.0185 | ||
Mean (SD) | 19.72 (11.90) | 17.57 (10.02) | |
HAQ-DI (0–3) | 0.0010 | ||
Mean (SD) | 1.82 (0.66) | 1.66 (0.63) | |
CRP (mg/L) | 0.3210 | ||
Mean (SD) | 24.90 (29.39) | 22.67 (24.22) | |
Oral glucocorticosteroid use, n (%) | 119 (64.7) | 1177 (61.0) | 0.3344 |
Mean (SD) prednisone equivalent dose, mg | 6.6 (2.63) | 6.6 (2.68) | 0.7462 |
Hydroxychloroquine use, n (%) | 4 (2.2) | 33 (1.7) | > 0.9999 |
Antidiabetic medication use, n (%) | 143 (77.7) | NR | NR |
Any noninsulin blood glucose-lowering drug, n (%)a | 85 (46.2) | NR | NR |
≥ 2 noninsulin blood glucose-lowering drugs, n (%)b | 32 (17.4) | NR | NR |
Any insulin and analogue without oral blood glucose lowering drug, n (%) | 13 (7.1) | NR | NR |
Any insulin and analogue plus oral blood glucose lowering drug, n (%) | 14 (7.6) | NR | NR |